IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Vinva Investment Management Ltd

Vinva Investment Management Ltd increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 14.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 8,324 shares of the medical research company’s stock after acquiring an additional 1,026 shares during the period. Vinva Investment Management Ltd’s holdings in IQVIA were worth $1,954,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Capital Performance Advisors LLP bought a new stake in IQVIA in the third quarter valued at $27,000. Park Place Capital Corp acquired a new stake in shares of IQVIA in the 3rd quarter worth about $28,000. Versant Capital Management Inc lifted its position in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new position in IQVIA during the 2nd quarter valued at about $27,000. Finally, Itau Unibanco Holding S.A. bought a new position in IQVIA in the 2nd quarter worth about $29,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

IQV has been the subject of several analyst reports. BTIG Research reduced their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Robert W. Baird reduced their price target on IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research report on Friday, November 1st. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price target on shares of IQVIA in a report on Friday, November 1st. Redburn Atlantic assumed coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. Finally, TD Cowen lowered their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Price Performance

Shares of NYSE:IQV opened at $200.96 on Friday. The company has a market capitalization of $36.47 billion, a PE ratio of 26.37, a price-to-earnings-growth ratio of 2.07 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a fifty day moving average of $218.67 and a 200-day moving average of $226.20. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.